| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Pyrazine-2-carbonitrile does not have a specific biological target itself but serves as a synthetic intermediate for the preparation of bioactive compounds. The pyrazine scaffold is found in various pharmaceuticals and agrochemicals. The nitrile group allows for further functionalization, including conversion to amides, carboxylic acids, or amines. The compound's role is to provide the pyrazine core for the synthesis of biologically active molecules.
|
|---|---|
| ln Vitro |
In vitro activity is not assessed for this compound itself, as it is a synthetic intermediate rather than a therapeutic agent. However, the compounds synthesized from it may exhibit various biological activities. The compound's utility lies in its ability to be converted into diverse bioactive molecules through various chemical transformations, including nitrile hydrolysis, reduction, and cycloaddition reactions.
|
| ln Vivo |
In vivo biological activity is not applicable for this compound, as it is a chemical intermediate used in synthesis rather than a therapeutic agent. Its applications are confined to chemical synthesis and materials science. No in vivo efficacy or pharmacological studies in animal models are available for this intermediate. The compound is not designed for systemic administration.
|
| Enzyme Assay |
Non-cellular experiments for this compound typically involve its use as a starting material in organic synthesis. A typical protocol includes using the compound in the synthesis of nitrogen-doped carbon nanoparticles by pyrolysis, or in the conversion of the nitrile group to amides, carboxylic acids, or amines. The compound can also be used in cycloaddition reactions to form fused heterocycles. Analytical methods such as TLC, HPLC, and NMR are used.
|
| Cell Assay |
Cell-based assays are not applicable for this compound, as it is a synthetic intermediate rather than a pharmacological agent. It is not tested in cell culture models for biological activity. The compound is used exclusively in chemical synthesis and materials science. Researchers should handle this compound with appropriate safety precautions.
|
| Animal Protocol |
In vivo animal studies are not performed with this compound in a therapeutic context. Its applications are confined to chemical synthesis and materials science. No efficacy or safety studies in animal models are available. The compound is not intended for human or veterinary use. Researchers should consult safety data sheets for handling and disposal guidelines.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not characterized for this compound, as it is a synthetic intermediate rather than a therapeutic agent. Its molecular weight is 105.10 g/mol, and it has slight solubility in water. The compound is stable under recommended storage conditions. No data on absorption, distribution, metabolism, or excretion are available.
|
| Toxicity/Toxicokinetics |
Toxicological data for this compound are limited. Nitriles can be toxic and should be handled with appropriate safety precautions. The compound is stable under recommended storage conditions. No carcinogenic or reproductive toxicity data are available. Researchers should consult the safety data sheet for specific hazard information and handling guidelines. The compound is not intended for human use.
|
| Additional Infomation |
Cyanopyrazine is a pyrazine compound and also a nitrile compound.
Pyrazine-2-carbonitrile is a synthetic intermediate used in organic synthesis and materials science. Its CAS number is 19847-12-2. The compound is used as a precursor for nitrogen-doped carbon nanoparticles and as a building block for pharmaceutical development. It is available with a purity of ≥97% from various suppliers. The compound is not approved for therapeutic use but is an important tool for chemical research. It should be stored in a cool, dry place. |
| Molecular Formula |
C5H3N3
|
|---|---|
| Molecular Weight |
105.10
|
| Exact Mass |
105.032
|
| CAS # |
19847-12-2
|
| PubChem CID |
73172
|
| Appearance |
Colorless to off-white <18°C solid powder,>20°C liquid
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
226.1±20.0 °C at 760 mmHg
|
| Melting Point |
18-20ºC
|
| Flash Point |
90.7±7.0 °C
|
| Vapour Pressure |
0.1±0.4 mmHg at 25°C
|
| Index of Refraction |
1.541
|
| LogP |
-0.15
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
8
|
| Complexity |
112
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
N#CC1=CN=CC=N1
|
| InChi Key |
PMSVVUSIPKHUMT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H3N3/c6-3-5-4-7-1-2-8-5/h1-2,4H
|
| Chemical Name |
pyrazine-2-carbonitrile
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~200 mg/mL (~1903.0 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (47.57 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (47.57 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 5 mg/mL (47.57 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (50.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 9.5147 mL | 47.5737 mL | 95.1475 mL | |
| 5 mM | 1.9029 mL | 9.5147 mL | 19.0295 mL | |
| 10 mM | 0.9515 mL | 4.7574 mL | 9.5147 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
